Share of the pharma major fell about 4 per cent in the first one hour of the trade on Friday. Experts see concerns over the US business, as well as, pressure on operating performance as key drags. Despite near-term headwinds, most brokerage firms maintained their rating and target prices but slashed earnings per share (EPS) estimates for FY23-24.
Sebi nod to Nuvama’s mutual fund entry, approves role as sponsor
Nuvama Wealth Management secured Sebi approval for its mutual fund business. This enables Nuvama to establish the proposed Nuvama Mutual Fund. The company can now
October 2, 2025